Sugi Predict

Sugi Predict / Compounds / SCHEMBL1240344

SCHEMBL1240344

SCHEMBL1240344

O=C(O)[C@H]1CC[C@@H](C(F)(F)F)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.43
▸ PLG P00747 1/20 0.43
▸ PLAT P00750 1/20 0.43
▸ TSHR P16473 2/20 0.42
▸ GABRP O00591 1/20 0.42
▸ GABRD O14764 1/20 0.42
▸ GABRA1 P14867 1/20 0.42
▸ GABRB1 P18505 1/20 0.42
▸ GABRG2 P18507 1/20 0.42
▸ GABRB3 P28472 1/20 0.42
▸ GABRA5 P31644 1/20 0.42
▸ GABRA3 P34903 1/20 0.42
▸ GABRA2 P47869 1/20 0.42
▸ GABRB2 P47870 1/20 0.42
▸ GABRA4 P48169 1/20 0.42
▸ GABRE P78334 1/20 0.42
▸ PMP22 Q01453 1/20 0.42
▸ GABRA6 Q16445 1/20 0.42
▸ GABRG1 Q8N1C3 1/20 0.42
▸ GABRG3 Q99928 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL671389 1.00 LMNA (0.43) LMNAPLGPLATTSHRGABRP
SCHEMBL671388 1.00 LMNA (0.43) LMNAPLGPLATTSHRGABRP
Hydrochloric Acid SCHEMBL1966991 0.98 LMNA (0.41) LMNAPLGPLATTSHRGABRP
Hydrochloric Acid SCHEMBL1966994 0.98 LMNA (0.41) LMNAPLGPLATTSHRGABRP
SCHEMBL28493088 0.86 ACE (0.39) LMNAPLGPLATTSHRGABRP
SCHEMBL28649535 0.82 CHRNB2 (0.38) —
SCHEMBL7113053 0.81 LMNA (0.40) LMNAPLGPLATTSHRGABRP
SCHEMBL28991866 0.81 LMNA (0.40) LMNAPLGPLATTSHRGABRP
SCHEMBL848914 0.81 LMNA (0.40) LMNAPLGPLATTSHRGABRP
Trifluoroacetic Acid SCHEMBL6256275 0.79 LMNA (0.46) LMNAPLGPLATTSHRGABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109724-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2026-04-23 — — US disclosed
EP-4107164-B1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 — — EP disclosed
US-12264173-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2025-04-01 — — US disclosed
US-20240174704-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2024-05-30 — — US disclosed
US-11767337-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2023-09-26 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
US-11572356-B2 Biaryl inhibitors of Bruton's tyrosine kinase BIOGEN MA INC. (US) 2023-02-07 — — US disclosed
US-20220356196-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2022-11-10 — — US disclosed
US-20220332705-A1 BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2022-10-20 — — US disclosed
CN-115087659-A Antiviral compounds 吉利德科学公司 2022-09-20 — — CN disclosed
US-20140296237-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2014-10-02 — — US disclosed
US-8809380-B2 Picolinamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2014-08-19 — — US disclosed
CN-103732597-A Tricyclic heterocyclic compounds and JAK inhibitors NISSAN CHEMICAL IND LTD 2014-04-16 — — CN disclosed
EP-2697232-A1 6,7 - DIHYDROIMIDAZO [2, 1 - B][1, 3]OXAZINE BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-02-19 — — EP disclosed
US-20140031342-A1 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-30 — — US disclosed
WO-2012141338-A1 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-18 — — WO disclosed
US-20120142691-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. 2012-06-07 — — US disclosed
US-20110053974-A1 CARBOXYLIC ACID COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-03 — — US disclosed
EP-2289868-A1 CARBOXYLIC ACID COMPOUND Daiichi Sankyo Company, Limited (JP) 2011-03-02 — — EP disclosed
WO-2011016234-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2011-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295201-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 LMNA 3047/4885PLG 4614/4885PLAT 2768/4885
US-11572356-B2 Biaryl inhibitors of Bruton's tyrosine kinase ABL1, BTK, LYN LMNA 2791/4885PLG 3717/4885PLAT 1980/4885
US-20110053974-A1 CARBOXYLIC ACID COMPOUND AKR1C3, SLC5A1, GPR119 LMNA 2035/4885PLG 3915/4885PLAT 4303/4885
US-20220356196-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 LMNA 3047/4885PLG 4614/4885PLAT 2768/4885
US-20120142691-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS CACNA1G, SCN3A, SCN5A LMNA 1079/4885PLG 2535/4885PLAT 3049/4885
US-20260109724-A1 ANTIVIRAL COMPOUNDS IRF3, IFNAR1, HAVCR2 LMNA 2428/4885PLG 4867/4885PLAT 4844/4885
US-12264173-B2 Antiviral compounds MAVS, HAVCR2, ZC3HAV1 LMNA 3047/4885PLG 4614/4885PLAT 2768/4885
US-11767337-B2 Antiviral compounds MAVS, HAVCR2, ZC3HAV1 LMNA 3047/4885PLG 4614/4885PLAT 2768/4885
US-20140296237-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS CACNA1G, SCN3A, SCN5A LMNA 1079/4885PLG 2535/4885PLAT 3049/4885
US-20240174704-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 LMNA 3047/4885PLG 4614/4885PLAT 2768/4885
US-20220332705-A1 BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, LYN LMNA 2791/4885PLG 3717/4885PLAT 1980/4885
US-20140031342-A1 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES BRD1, OXA1L, QDPR LMNA 4252/4885PLG 4230/4885PLAT 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.